Resiquimod
TLR7/8 agonist / Immune adjuvant / A Toll-like receptor 7/8 agonist.1 May be used as an immune adjuvant in cancer vaccines.2 Resiquimod-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.3 Topical treatment of wild-type mice induces systemic autoimmune disease which may be used as a model of systemic Lupus erythematosus.4
Biochemicals & reagents
144875-48-9
R848
1) Jurk et al. (2002), Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848; Nat. Immunol., 3 499 2) Sabado et al. (2015), Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma; Cancer Immunol. Res., 3 278 3) Ilyinskii et al. (2014), Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release; Vaccine, 32 2882 4) Yokogawa et al. (2014), Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erthematosus.; Arthritis Rheumatol., 66 694
-20°C
TARGET: TLR (Toll-like receptor) -- PATHWAY: TLR signaling; Cytokine -- RESEARCH AREA: Immunology -- DISEASE AREA: Cancer; Infectious disease